Mercados españoles cerrados

Grifols, S.A. (GRF.MC)

MCE - MCE Precio demorado. Divisa en EUR
Añadir a la lista de favoritos
19,90+0,12 (+0,63%)
Al cierre: 05:35PM CEST

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del Vallès
Barcelona 08174
Spain
34 93 571 02 21
https://www.grifols.com

Sector(es)Healthcare
SectorDrug Manufacturers—General
Empleados a tiempo completo23.245

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Raimon Grifols RouraCo-CEO & Exec. Director895kN/A1964
Mr. Víctor Grifols DeuCo-CEO & Exec. Director895kN/A1977
Mr. Alfredo Arroyo GuerraCFO & VPN/AN/A1958
Mrs. Eva Bastida TubauCorp. VP and Director of Scientific & Medical AffairsN/AN/AN/A
Ms. Nuria Pascual LapeñaVP of Corp. Treasury, Risk Management Investor Relation & Sustainability OfficerN/AN/A1964
Mr. David Ian BellGen. Counsel & Chief Corp. Devel. OfficerN/AN/A1955
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/AN/A1965
Mr. Mateo Florencio Borrás HumbertCorp. VP & Chief HR OfficerN/AN/A1956
Ms. Montserrat Gaja LlamasChief HR OfficerN/AN/A1965
Mr. Francisco Javier Jorba RibesCorp. VP and Pres of the Biological Industrial GroupN/AN/A1951
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Gobierno corporativo

El ISS Governance QualityScore de Grifols, S.A., a día 1 de mayo de 2022, es 4. Las puntuaciones base son Auditoría: 6; Tablero: 3; Derechos de los accionistas: 8; Compensación: 2.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.